Osteopontin: an emerging therapeutic target for anticancer therapy.
Distant migration of malignant cells or metastasis is considered one of the hallmarks of tumour progression and makes cancer a most deadly disease. The elevated expression of osteopontin (OPN), a metastasis-associated small integrin-binding ligand N-linked glycoprotein family member has been observed in several cancers and, thus, this protein is considered as a potent prognostic marker during tumour progression. OPN regulates a series of signalling cascades and augments the expression of several oncogenic molecules. Therefore, understanding the molecular mechanism and the signalling pathways by which OPN promotes tumorigenesis may be helpful in designing a novel anticancer therapy. At present, the role of OPN in regulating cancer progression is the subject of intense investigation and targeting OPN might be an appropriate therapeutic strategy for the treatment of cancer. This review is focused on OPN-based anticancer therapy, which may provide a new dimension for the successful treatment of cancer.
Jain
Shalini
S
National Center for Cell Science, Pune-411007, India.
Chakraborty
Goutam
G
Bulbule
Anuradha
A
Kaur
Rajinder
R
Kundu
Gopal C
GC
D000818:Animals; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D006801:Humans; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D009389:Neovascularization, Pathologic; D053495:Osteopontin / Q000378:metabolism*
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D053495:Osteopontin